Arterial hypertension and cardiac arrhythmias

Journal of Hypertension

Volumn 19, Issue 2, 2001, Pages 167-177

  Hennersdorf, Marcus G ^a   Strauer, Bodo E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Arrhythmia; Arterial hypertension

Indexed keywords

ADULT; AGED; CONTROLLED STUDY; ELECTROCARDIOGRAM; EXTRASYSTOLE; FEMALE; HEART ATRIUM ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MALE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; ST SEGMENT DEPRESSION; SUDDEN DEATH;

EID: 0035143324     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200102000-00002     Document Type: Review

References (109)

1. Systolic blood pressure and mortality
2. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
3. Recent advances in cardiac hypertrophy
4. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study
5. The significance of coronary reserve in clinical heart disease
6. Coronary flow studies in patients with left ventricular hypertrophy of the hypertensive type
7. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy
8. Transient myocardial ischemias in hypertensive patients
9. Mechanisms of angina pectoris with essential hypertension and normal epicardial arteries by arteriogram
10. Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms
11. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension
12. Compensated cardiac hypertrophy: Arrhythmogeneicity and the new myocardial phenotype. I. Fibrosis
13. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system
14. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension
15. Myocardial oxygen consumption in chronic heart disease: Role of wall stress, hypertrophy and coronary reserve
16. Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective
17. Risk mechanisms in hypertensive heart disease
18. Cellular mechanisms of arrhythmias in hypertrophied and failing myocardium
19. Effects of contraction-excitation feedback on electrophysiology and arrhythmogenesis in rabbits with experimental left ventricular hypertrophy
20. Electrophysiologic consequences of chronic experimentally induced left ventricular pressure overload
21. Electrophysiological remodeling in hypertrophy and heart failure
22. 2+ handling and vulnerability to ventricular fibrillation in spontaneously hypertensive rats
23. Effects of hypertrophy on regional action potential characteristics in the rat left ventricle. A cellular basis for t-wave inversion?
24. Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR
25. Ventricular arrhythmias in hypertensive heart disease with and without heart failure
26. Ventricular arrhythmias in left ventricular hypertrophy and heart failure
27. Mechanical and non-mechanical factors in hypertensive hypertrophy, their clinical roles
28. Diastolic functions and atrial arrhythmias in patients with arterial hypertension
29. What is the role of silent coronary artery disease and left ventricular hypertrophy in the genesis of ventricular arrhythmias in men with essential hypertension?
30. Prevalence of circadian variations and spontaneous variability of cardiac disorders and ECG changes suggestive of myocardial ischemias in systemic arterial hypertension
31. Mechanisms of ventricular arrhythmias in the presence of pathological hypertrophy
32. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease
33. Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade
34. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction
35. Acute changes in blood pressure as a cause of cardiac arrhythmias
36. Hypertension and sudden death. Disparate effects of calcium entry blocker and diuretic therapy on cardiac arrhythmias
37. Epidemiologic features of chronic atrial fibrillation. The Framingham study
38. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study
39. Pathophysiology, epidemiology and complications of atrial fibrillation
40. Risk factors for systemic embolism in patients with paroxysmal atrial fibrillation
41. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk
42. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk
43. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Analysis of 2012 participants in the SPAF I-III clinical trials
44. Drug use in patients with atrial fibrillation in Swedish primary health care: A comparison 5 years apart
45. Quality of anticoagulation management among patients with atrial fibrillation. Results of a review of medical records from 2 communities
46. Screening for atrial fibrillation in primary care
47. Atrial fibrillation: Current knowledge and recommendations for management
48. Preventing stroke in patients with atrial fibrillation
49. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension
50. Detection of hypertensive patients at risk for paroxysmal atrial fibrillation during sinus rhythm by computer-assistes P wave analysis
51. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study
52. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy
53. Hypertensive concentric left ventricular hypertrophy: When is ventricular ectopic activity increased?
54. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease
55. Prognostic value of ventricular arrhythmias in systemic hypertension
56. Significance of QTc prolongation on ventricular arrhythmias in patients with left ventricular hypertrophy secondary to essential hypertension
57. Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy
58. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death
59. Arterial hypertension, left ventricular hypertrophy and sudden cardiac death
60. Myocardial ischemia and ventricular arrhythmias in relation to left ventricular mass and resistance artery structure
61. Cardiac prognosis in hypertensive patients. Incidence of sudden death and ventricular arrhythmias
62. Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension
63. Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy
64. Hypertensive heart disease and endocardially recorded late potentials
65. Standards for analysis of ventricular late potentials using high resolution or signal-averaged electrocardiography
66. Late potentials and heart rate variability in heart muscle disease
67. The arrhythmogenic risk of left ventricular hypertrophy
68. Prognostic value of arrhythmogenic markers in systemic hypertension
69. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden cardiac death
70. Reduced heart rate variability and new-onset hypertension. Insights into pathogenesis of hypertension: The Framingham Heart Study
71. Alterations in heart rate variability and its circadian rhythm in hypertensive patients with left ventricular hypertrophy free of coronary artery disease
72. Heart rate variability in left ventricular hypertrophy
73. Dispersion of the QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy
74. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction
75. Baroreflex sensitivity in drug-treated systemic hypertension
76. Autonomic and baroreflex function after captopril in hypertension
77. Effects of combination antihypertensive therapy on baroreflex sensitivity and heart rate variability in systemic hypertension
78. QTc dispersion predicts cardiac mortality in the elderly. The Rotterdam Study
79. QT interval dispersion and its clinical utility
80. Left ventricular geometric patterns and QT dispersion in untreated essential hypertension
81. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: Relation to autonomic nervous system and Holter tape abnormalities
82. Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril
83. Irbesartan reduces QT dispersion in hypertensive individuals
84. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension
85. Electrical alternans and vulnerability to ventricular arrhythmias
86. T-wave alternans as a risk predictor in patients with cardiomyopathy and mild to moderate heart failure
87. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
88. Left ventricular hypertrophy as a risk factor in arterial hypertension
89. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade
90. Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart
91. Restoration of action potential duration and tranient outward current by regression of left ventricular hypertrophy
92. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension
93. Cardiac arrhythmias in hypertension. Prospective study including 251 patients. Efficacy of sotalol
94. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
95. Management of atrial fibrillation: Therapeutical options and clinical decisions
96. Sotalol
97. Quinidine-related mortality in the short-to medium-term treatment of ventricular arrhythmias. A meta-analysis
98. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: A meta analysis
99. Amiodarone: Reevaluation of an old drug
100. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: The effect of no treatment and high-dose amiodarone
101. Amiodarone to prevent recurrence of atrial fibrillation
102. Clinical outcome after ablation and pacing therapy for atrial fibrillation: A meta-analysis
103. Prevention of atrial fibrillation by atrial pacing
104. Newer applications of pacing
105. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation
106. Two-staged biatrial linear and focal ablation to restore sinus rhythm in patients with refractory chronic atrial fibrillation: Procedure experience and follow-up beyond 1 year
107. Management of ventricular arrhythmias
108. Catheter ablation of ventricular tachycardia